medigraphic.com
ISSN 2594-3006 (Electronic)
ISSN 2007-1752 (Print)
Archivos de Medicina de Urgencia de México

2024, Number 3

<< Back Next >>

Arch Med Urg Mex 2024; 16 (3)

Type 2 diabetes mellitus, severity and mortality in ARDS due to COVID 19

Bautista-Ramírez A, Sosa-Jurado F, Alvarado-Dardón K

Language: Spanish
References: 32
Page: 204-209
PDF size: 190.24 Kb.


ABSTRACT

Since December 2019, the first cases of a recently discovered disease that would eventually spread worldwide have appeared in Wuhan (Hubei province) and other provinces of China; the new disease called COVID-19, which has as its pathogen the new coronavirus 2019, which causes the highly contagious severe acute respiratory syndrome (SARS-CoV-2).
Introduction: since december 2019, the first cases of a new disease caused by the causative agent called the new coronavirus 2 (SARSCoV- 2)1 have been reported, which spread rapidly throughout the world and has since generated 103,201,340 confirmed cases worldwide, which was called COVID-19, with a mortality rate of 2,237,636 according to reports obtained from the COVID-19 control center located at the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University.


REFERENCES

  1. Liu Z, Bai X, Han X et al. The association of diabetes and the prognosisof COVID-19 patients: A retrospective study. Diabetes ResClin Pract. 2020; 169:108386. doi:10.1016/j.diabres.2020.108386

  2. Corrao S, Pinelli K, Vacca M, Raspanti M, Argano C. Type 2 DiabetesMellitus and COVID-19: A Narrative Review. Front Endocrinol.2021;12. doi:10.3389/fendo.2021.609470

  3. Kothandaraman N, Anantharaj R, Xue B et al. COVID-19 Endocrinopathywith Hindsight from SARS. Am J Physiol EndocrinolMetab. 2020. doi:10.1152/ajpendo.00480.2020

  4. Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetesmellitus: from pathophysiology to clinical management. Nat RevEndocrinol. 2020;17(1):11-30. doi:10.1038/s41574-020-00435-4

  5. Steenblock C, Schwarz PE, Ludwig B et al. COVID-19 and metabolicdisease: mechanisms and clinical management. Lancet DiabetesAmp Endocrinol. 2021;9(11):786-798. doi:10.1016/s2213-8587(21)00244-8

  6. Landstra CP, de Koning EJ. COVID-19 and Diabetes: Understandingthe Interrelationship and Risks for a Severe Course. FrontEndocrinol. 2021;12. doi:10.3389/fendo.2021.649525

  7. Standards of Medical Care in Diabetes—2022 Abridged for PrimaryCare Providers. Clin Diabetes. 2022;40(1):10-38. doi:10.2337/cd22-as01

  8. Galicia-Garcia U, Benito-Vicente A, Jebari S et al. Pathophysiologyof Type 2 Diabetes Mellitus. Int J Mol Sci. 2020;21(17):6275.doi:10.3390/ijms21176275

  9. Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 Diabetesand its Impact on the Immune System. Curr Diabetes Rev.2020;16(5):442-449. doi:10.2174/1573399815666191024085838

  10. Viigimaa M, Sachinidis A, Toumpourleka M, KoutsampasopoulosK, Alliksoo S, Titma T. Macrovascular Complications of Type 2 DiabetesMellitus. Curr Vasc Pharmacol. 2020;18(2):110-116. doi:10.2174/1570161117666190405165151

  11. Seid MA, Akalu Y, Gela YY et al. Microvascular complications andits predictors among type 2 diabetes mellitus patients at Dessietown hospitals, Ethiopia. Diabetol Amp Metab Syndr. 2021;13(1).doi:10.1186/s13098-021-00704-w

  12. Vassiliou AG, Kotanidou A, Dimopoulou I, Orfanos SE. EndothelialDamage in Acute Respiratory Distress Syndrome. Int J Mol Sci.2020;21(22):8793. doi:10.3390/ijms21228793

  13. Meyer NJ, Gattinoni L, Calfee CS. Acute respiratory distress syndrome.Lancet. 2021;398(10300):622-637. doi:10.1016/s0140-6736(21)00439-6

  14. Morales Fernández JA, Wong Chew RM. Generalidades, aspectosclínicos y de prevención sobre COVID-19: México y Latinoamérica.Univ Medica. 2021;62(3). doi:10.11144/javeriana.umed62-3.gacp

  15. Ball L, Silva PL, Giacobbe DR et al. Understanding the pathophysiologyof typical acute respiratory distress syndrome and severeCOVID-19. Expert Rev Respir Med. 2022:1-10. doi:10.1080/17476348.2022.2057300

  16. Abdi A, Jalilian M, Sarbarzeh PA, Vlaisavljevic Z. Diabetes andCOVID-19: A systematic review on the current evidences. DiabetesRes Clin Pract. 2020; 166:108347. doi:10.1016/j.diabres.2020.108347

  17. Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A,Del Prato S. COVID-19 in people with diabetes: understanding thereasons for worse outcomes. Lancet Diabetes Amp Endocrinol.2020;8(9):782-792. doi:10.1016/s2213-8587(20)30238-2

  18. Xu Z, Wang Z, Wang S, et al. The impact of type 2 diabetes and itsmanagement on the prognosis of patients with severe COVID‐19.Journal of Diabetes. 2020;12(12):909-918. doi:10.1111/1753-0407.13084

  19. Tadic M, Cuspidi C, Sala C. COVID‐19 and diabetes: Is there enoughevidence? J Clin Hypertens. 2020;22(6):943-948. doi:10.1111/jch.13912

  20. Kumar A, Arora A, Sharma P et al. Is diabetes mellitus associatedwith mortality and severity of COVID-19? A meta-analysis.Diabetes Amp Metab Syndr. 2020; 14(4):535-545. doi:10.1016/j.dsx.2020.04.044

  21. James PT, Ali Z, Armitage AE et al. The Role of Nutrition in COVID-19 Susceptibility and Severity of Disease: A Systematic Review.J Nutr. 2021; 151(7):1854-1878. doi:10.1093/jn/nxab059

  22. Amoretti M, Amsler C, Bonomi G et al. Production and detectionof cold antihydrogen atoms. Nature. 2002;419(6906):456-459.doi:10.1038/nature01096

  23. Erener S. Diabetes, infection risk and COVID-19. Molecular Metabolism.2020; 39:101044. doi:10.1016/j.molmet.2020.101044

  24. Rajpal A, Rahimi L, Ismail‐Beigi F. Factors leading to highmorbidity and mortality of COVID ‐19 in patients with type 2diabetes. J Diabetes. 2020; 12(12):895-908. doi:10.1111/1753-0407.13085

  25. Zhu L, She ZG, Cheng X, et al. Association of Blood GlucoseControl and Outcomes in Patients with COVID-19 and Pre-existingType 2 Diabetes. Cell Metabolism. 2020;31(6):1068-1077.e3.doi:10.1016/j.cmet.2020.04.021

  26. Pranata R, Henrina J, Raffaello WM, Lawrensia S, Huang I. Diabetesand COVID-19: The past, the present, and the future. Metabolism,Clinical and Experimental. 2021; 121:154814. doi:10.1016/j.metabol.2021.154814

  27. Sabri S, Bourron O, Phan F, Nguyen LS. Interactions between diabetesand COVID-19: A narrative review. World J Diabetes. 2021;12(10):1674-1692. doi:10.4239/wjd.v12.i10.1674

  28. Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19:a systematic review and meta-analysis of 42 studies and 423,117patients. BMC Infect Dis. 2021; 21(1). doi:10.1186/s12879-021-06536-3

  29. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021; 184(4):861-880. doi:10.1016/j.cell.2021.01.007

  30. Chen J, Wu C, Wang X, Yu J, Sun Z. The Impact of COVID-19on Blood Glucose: A Systematic Review and Meta-Analysis. FrontEndocrinol. 2020;11. doi:10.3389/fendo.2020.574541

  31. Vindrola-Padros C, Singh KE, Sidhu MS et al. Remote homemonitoring (virtual wards) for confirmed or suspected COVID-19patients: a rapid systematic review. EClinicalMedicine. 2021;37:100965. doi:10.1016/j.eclinm.2021.100965

  32. Booth A, Reed AB, Ponzo S et al. Population risk factors for severedisease and mortality in COVID-19: A global systematic review andmeta-analysis. PLOS ONE. 2021;16(3):e0247461. doi:10.1371/journal.pone.0247461




2020     |     www.medigraphic.com